			7
	Application No.	Applicant(s)	
	10/045,595	TAVARES ET AL.	
Notice of Allowability	Examiner	Art Unit	
<u> </u>	Isis Ghali	1615	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to <u>06/06/2005</u> .			
2. The allowed claim(s) is/are 1,3-5,7-10,12-16,20,22-26,28,30-38 and 40-47.			
3. The drawings filed on 31 May 2002 are accepted by the Examiner.			
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 			
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.			
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 			
DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
	•		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. ☐ Notice of Informal P	tatent Application (PT)	O.152\
Notice of References Cited (FTO-092) Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary		J- 102)
	Paper No./Mail Dat	te	
 Information Disclosure Statements (PTO-1449 or PTO/SB/C Paper No./Mail Date 6/13/03;11/8/04 	•		
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	ent of Reasons for Allo	wance
of Biological Material	9.		$\overline{}$
•		THURMAN SUPERVISORY PAY TECHNOLOGY C	R PAGE ENT EXAMINER ENTER 1600

Application/Control Number: 10/045,595 Page 2

Art Unit: 1615

The receipt is acknowledged of applicants' amendment filed 06/06/2005.

Allowable Subject Matter

1. Claims 1, 3-5, 7-10, 12-16, 20, 22-26, 28, 30-38, 40-47 are allowed.

2. The following is an examiner's statement of reasons for allowance: the closest prior art does not teach or suggest method of treating hypertension or angina in a human patient by administering transdermal device comprising felodipine that provides therapeutic blood levels of the felodipine within 36 hr, and maintains effective the therapeutic level for 3 days, wherein the device having a mean relative release rate of from about 4.2 μ g/cm²/hr to 20.0 μ g/cm²/hr at 24 hr, from 3.3 μ g/cm²/hr to 14.0 μ g/cm²/hr at 48 hr, and from 2.7 μ g/cm²/hr to 10.8 μ g/cm²/hr at 72 hr as determined by Valia-Chien cell; and the device provides plasma level of felodipine of at least 0.1 ng/ml within about 6 hr after application to the skin.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 10/045,595 Page 3

Art Unit: 1615

3. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Isis Ghali whose telephone number is (571) 272-0595.

The examiner can normally be reached on Monday-Thursday, 7:00 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Thurman Page can be reached on (571) 272-0602. The fax phone number

for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Isis Ghali

Examiner

Art Unit 1615

IG

THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TEGHNOLOGY CENTER 1600